IL17A and psoriasis: As strategies to block interleukin 1 have not been effective in treating psoriasis (16), the question arises whether IL-17A or other cytokines like TNFα, IL-12/23 (p40), or IL-23 might be a therapeutic target that would allow achieving therapeutic effects beyond the skin and joints, namely regarding the cardiometabolic situation of the patients.